Iptacopan (2) – Fabhalta®
Complement-3 glomerulopathy
Characteristics
| Start date | 01.05.2025 |
|---|---|
| Resolution | 21.08.2025 |
| INN | Iptacopan |
| Brand name | Fabhalta® |
| Pharm. company | Novartis Pharma GmbH |
| G-BA Procedure ID | D-1186 |
| Therapeutic area | Genitourinary system diseases Orphan |
| Reason for procedure | not completed: discontinued |
Associated procedures
| Iptacopan (4) | Fabhalta® | Novartis Pharma GmbH | Complement-3 glomerulopathy | 110–230 | 100% additional benefit not proven Orphan (turnover limit) | |
| Iptacopan (3) | Fabhalta® | Novartis Pharma GmbH | Paroxysmal nocturnal haemoglobinuria | 290–945 | 100% additional benefit not proven Orphan (turnover limit) | |
| Iptacopan (2) | Fabhalta® | Novartis Pharma GmbH | Complement-3 glomerulopathy | n.d. | discontinued Orphan | |
| Iptacopan (1) | Fabhalta® | Novartis Pharma GmbH | Paroxysmal nocturnal hemoglobinuria |
0
290–945 |
100% Hint for non-quantifiable additional benefit Orphan repealed |
<< List of all resolutions